Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

NCT02579759 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

323

Enrollment

OTHER

Sponsor class

Conditions

Charcot-Marie-Tooth Disease Type 1A

Interventions

DRUG: PXT3003 dose 1
DRUG: PXT3003 dose 2
DRUG: placebo

Sponsor

Pharnext S.C.A.